Milazzo Eliana, Orellana Gabriela, Briceño-Bierwirth Adriana, Korrapati Vamsi Kiran
Department of Internal Medicine, Texas Tech University Health Sciences Center School of Medicine, Odessa, Texas, USA
Department of Internal Medicine, Texas Tech University Health Sciences Center School of Medicine, Odessa, Texas, USA.
BMJ Case Rep. 2021 Apr 14;14(4):e237571. doi: 10.1136/bcr-2020-237571.
Nitrofurantoin is a synthetic derivative of imidazolinedione, used to treat uncomplicated urinary tract infections. It acts by inhibiting bacterial DNA, RNA and cell wall protein synthesis. It is used prophylactically as a urinary anti-infective agent against most gram-positive organism and for long-term suppression of infections. Nitrofurantoin-associated pulmonary injuries occur in 1% of patients, presenting with dyspnoea and dry cough, and it can mimic interstitial lung disease. We present a case of an 81-year-old woman with shortness of breath and cough 3 days after initiation of nitrofurantoin. CT of the chest revealed bilateral pleural effusion and extensive pulmonary interstitial prominence, suggesting pulmonary fibrosis. According to the Naranjo Adverse Drug Reaction Probability Scale score of 6, it was determined that nitrofurantoin was the probable cause, and immediate cessation of the medication showed a marked clinical improvement and resolution after 10 days.
呋喃妥因是咪唑啉二酮的合成衍生物,用于治疗非复杂性尿路感染。它通过抑制细菌DNA、RNA和细胞壁蛋白质合成发挥作用。它作为一种尿路抗感染药物,预防性地用于对抗大多数革兰氏阳性菌,并用于长期抑制感染。1%的患者会出现呋喃妥因相关的肺部损伤,表现为呼吸困难和干咳,且可能类似间质性肺病。我们报告一例81岁女性患者,在开始使用呋喃妥因3天后出现呼吸急促和咳嗽。胸部CT显示双侧胸腔积液和广泛的肺间质突出,提示肺纤维化。根据Naranjo药物不良反应概率量表评分为6分,确定呋喃妥因是可能的病因,立即停药后10天临床症状明显改善并消退。